These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37073657)

  • 1. Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras.
    Hamilton G; Stickler S; Rath B
    Curr Pharm Des; 2023; 29(22):1741-1746. PubMed ID: 37073657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of PROTACS degrading KRAS and SOS1.
    Hamilton G; Eggerstorfer MT; Stickler S
    Oncol Res; 2024; 32(8):1257-1264. PubMed ID: 39055890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of LHF418 as a new potent SOS1 PROTAC degrader.
    Li H; Chai M; Chen Y; Zhou F; Ren X; Xu J; Wang J; Wang Z; Huang W
    Bioorg Med Chem; 2024 Apr; 103():117661. PubMed ID: 38489998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
    Sudhakar N; Yan L; Qiryaqos F; Engstrom LD; Laguer J; Calinisan A; Hebbert A; Waters L; Moya K; Bowcut V; Vegar L; Ketcham JM; Ivetac A; Smith CR; Lawson JD; Rahbaek L; Clarine J; Nguyen N; Saechao B; Parker C; Elliott AJ; Vanderpool D; He L; Hover LD; Fernandez-Banet J; Coma S; Pachter JA; Hallin J; Marx MA; Briere DM; Christensen JG; Olson P; Haling J; Khare S
    Mol Cancer Ther; 2024 Oct; 23(10):1418-1430. PubMed ID: 38904222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Son of Sevenless 1: The pacemaker of KRAS.
    Kessler D; Gerlach D; Kraut N; McConnell DB
    Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor.
    Wang K; Zhou Z; Ma X; Xu J; Xu W; Zhou G; Zhou C; Li H; Zheng M; Zhang S; Xu T
    Bioorg Med Chem Lett; 2024 Jul; 107():129780. PubMed ID: 38714262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
    Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
    Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
    Ramharter J; Kessler D; Ettmayer P; Hofmann MH; Gerstberger T; Gmachl M; Wunberg T; Kofink C; Sanderson M; Arnhof H; Bader G; Rumpel K; Zöphel A; Schnitzer R; Böttcher J; O'Connell JC; Mendes RL; Richard D; Pototschnig N; Weiner I; Hela W; Hauer K; Haering D; Lamarre L; Wolkerstorfer B; Salamon C; Werni P; Munico-Martinez S; Meyer R; Kennedy MD; Kraut N; McConnell DB
    J Med Chem; 2021 May; 64(10):6569-6580. PubMed ID: 33719426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo.
    Pang X; Cui D; Lv B; Wang CY
    J Med Chem; 2024 Jan; 67(2):1563-1579. PubMed ID: 38206836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations.
    Zhou C; Fan Z; Zhou Z; Li Y; Cui R; Liu C; Zhou G; Diao X; Jiang H; Zheng M; Zhang S; Xu T
    J Med Chem; 2022 Mar; 65(5):3923-3942. PubMed ID: 35230841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of KRAS
    Zhang X; Zhao T; Sun M; Li P; Lai M; Xie L; Chen J; Ding J; Xie H; Zhou J; Zhang H
    Bioorg Med Chem; 2023 Jan; 78():117153. PubMed ID: 36621179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of SOS1 Inhibitor-Based Degraders to Target
    Bian Y; Alem D; Beato F; Hogenson TL; Yang X; Jiang K; Cai J; Ma WW; Fernandez-Zapico M; Tan AC; Lawrence NJ; Fleming JB; Yuan Y; Xie H
    J Med Chem; 2022 Dec; 65(24):16432-16450. PubMed ID: 36459180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of highly potent and selective KRAS
    Yang N; Fan Z; Sun S; Hu X; Mao Y; Jia C; Cai X; Xu T; Li B; Li Y; Han L; Wei T; Qian X; Qin W; Li P; Zheng Z; Li S
    Eur J Med Chem; 2023 Dec; 261():115857. PubMed ID: 37852032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting RAS oncogenesis with SOS1 inhibitors.
    Hillig RC; Bader B
    Adv Cancer Res; 2022; 153():169-203. PubMed ID: 35101230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
    Ketcham JM; Haling J; Khare S; Bowcut V; Briere DM; Burns AC; Gunn RJ; Ivetac A; Kuehler J; Kulyk S; Laguer J; Lawson JD; Moya K; Nguyen N; Rahbaek L; Saechao B; Smith CR; Sudhakar N; Thomas NC; Vegar L; Vanderpool D; Wang X; Yan L; Olson P; Christensen JG; Marx MA
    J Med Chem; 2022 Jul; 65(14):9678-9690. PubMed ID: 35833726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.
    Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
    Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
    Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
    Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers.
    Chen T; Tang X; Wang Z; Feng F; Xu C; Zhao Q; Wu Y; Sun H; Chen Y
    Eur J Med Chem; 2023 Dec; 261():115828. PubMed ID: 37778239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.